The Federal laws attacking tobacco use have been in the works for a long time. It seems as if the legislation is custom tailored to benefit Patent GMO low nicotine tobacco. A tobacco that would never be worth investing in without a promise of future federal legislation. A tobacco that couldn't be grown affordably by small business tobacco companies. A tobacco that has it's genes chimerically altered. A tobacco that tax payers will be paying millions to push on the public, while they fund scare campaigns against heirloom strains of tobacco.
http://www.xxiicentury.com/history/
From 2005 to 2009, 22nd Century partnered again with NCSU and with other public institutions for further R&D that included the cloning of additional nicotine biosynthesis genes...22nd Century’s model of outsourcing R&D to world-renowned plant biotechnology centers has enabled 22nd Century to maintain strict control of its R&D costs, while providing the company broad access to large public institutions’ infrastructure and transdisciplinary expertise. As a result, 22nd Century has obtained exclusive rights to all key nicotine biosynthesis genes that can be regulated to produce viable commercial products with modified
https://www.fda.gov/tobaccoproducts/labeling/rulesregulationsguidance/ucm246129.htm
To protect the public and create a healthier future for all Americans, the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), signed into law on June 22, 2009, gives FDA authority to regulate the manufacture, distribution, and marketing of tobacco products.
https://www.fda.gov/TobaccoProducts/Labeling/Labeling/ucm257774.htm
The Family Smoking Prevention and Tobacco Control Act requires the FDA to include new warning labels on cigarette packages and in cigarette advertisements. On June 22, 2011, the FDA published a final rule requiring color graphics depicting the negative health consequences of smoking to accompany the nine new textual warning statements.
http://www.xxiicentury.com/history/
2011 was quite an eventful year for the company... 22nd Century received FDA clearance for its Investigational New Drug (IND) Application in July and sponsored a Phase II-B clinical trial for its X-22 smoking cessation aid in development, a prescription-based smoking cessation aid consisting of a kit of very low nicotine (VLN) cigarettes. 22nd Century licensed Heracles Pharmaceuticals LLC, its pharmaceutical subsidiary, exclusive worldwide rights to X-22.
Other notable company events that occurred in 2011: 22nd Century entered into a 3-year R&D agreement with University of Virginia, and Goodrich Tobacco Company, LLC, 22nd Century’s tobacco product subsidiary, introduced two super-premium cigarette brands into the U.S. market and delivered more than 9 million SPECTRUM® research cigarettes. SPECTRUM® was developed by 22nd Century for NIDA, a department of the National Institutes of Health (NIH), and is strictly for independent research purposes.
http://ir.xxiicentury.com/press-releases/detail/314/fdas-plan-to-lower-nicotine-in-cigarettes-has-captured-the
In contrast, 22nd Century already possesses proven technology to grow tobacco with non-addictive levels of nicotine. The Company has an inventory of Very Low Nicotine tobacco varieties and is currently developing additional, improved Very Low Nicotine tobacco varieties, including non-GMO varieties.
The Bloomberg article concludes with the assertion that the FDA plan could lead to “the most fundamental change the tobacco industry has ever seen,” as stated by Matthew Myers, president of anti-smoking group Campaign for Tobacco-Free Kids.
“These are very exciting times; public health officials around the world are now actively considering mandates of nicotine levels in tobacco cigarettes made possible by 22nd Century,” explained Henry Sicignano, III, President and Chief Executive Officer of 22nd Century Group. “As other countries seek to implement their own reduced nicotine standards, 22nd Century stands ready to partner with any countries – or tobacco companies – that have a genuine interest in improving the health of smokers.”
http://www.xxiicentury.com/history/
From 2005 to 2009, 22nd Century partnered again with NCSU and with other public institutions for further R&D that included the cloning of additional nicotine biosynthesis genes...22nd Century’s model of outsourcing R&D to world-renowned plant biotechnology centers has enabled 22nd Century to maintain strict control of its R&D costs, while providing the company broad access to large public institutions’ infrastructure and transdisciplinary expertise. As a result, 22nd Century has obtained exclusive rights to all key nicotine biosynthesis genes that can be regulated to produce viable commercial products with modified
https://www.fda.gov/tobaccoproducts/labeling/rulesregulationsguidance/ucm246129.htm
To protect the public and create a healthier future for all Americans, the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), signed into law on June 22, 2009, gives FDA authority to regulate the manufacture, distribution, and marketing of tobacco products.
https://www.fda.gov/TobaccoProducts/Labeling/Labeling/ucm257774.htm
The Family Smoking Prevention and Tobacco Control Act requires the FDA to include new warning labels on cigarette packages and in cigarette advertisements. On June 22, 2011, the FDA published a final rule requiring color graphics depicting the negative health consequences of smoking to accompany the nine new textual warning statements.
http://www.xxiicentury.com/history/
2011 was quite an eventful year for the company... 22nd Century received FDA clearance for its Investigational New Drug (IND) Application in July and sponsored a Phase II-B clinical trial for its X-22 smoking cessation aid in development, a prescription-based smoking cessation aid consisting of a kit of very low nicotine (VLN) cigarettes. 22nd Century licensed Heracles Pharmaceuticals LLC, its pharmaceutical subsidiary, exclusive worldwide rights to X-22.
Other notable company events that occurred in 2011: 22nd Century entered into a 3-year R&D agreement with University of Virginia, and Goodrich Tobacco Company, LLC, 22nd Century’s tobacco product subsidiary, introduced two super-premium cigarette brands into the U.S. market and delivered more than 9 million SPECTRUM® research cigarettes. SPECTRUM® was developed by 22nd Century for NIDA, a department of the National Institutes of Health (NIH), and is strictly for independent research purposes.
http://ir.xxiicentury.com/press-releases/detail/314/fdas-plan-to-lower-nicotine-in-cigarettes-has-captured-the
In contrast, 22nd Century already possesses proven technology to grow tobacco with non-addictive levels of nicotine. The Company has an inventory of Very Low Nicotine tobacco varieties and is currently developing additional, improved Very Low Nicotine tobacco varieties, including non-GMO varieties.
The Bloomberg article concludes with the assertion that the FDA plan could lead to “the most fundamental change the tobacco industry has ever seen,” as stated by Matthew Myers, president of anti-smoking group Campaign for Tobacco-Free Kids.
“These are very exciting times; public health officials around the world are now actively considering mandates of nicotine levels in tobacco cigarettes made possible by 22nd Century,” explained Henry Sicignano, III, President and Chief Executive Officer of 22nd Century Group. “As other countries seek to implement their own reduced nicotine standards, 22nd Century stands ready to partner with any countries – or tobacco companies – that have a genuine interest in improving the health of smokers.”
